Literature DB >> 19479877

The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation.

Magdalena Koziczak-Holbro1, Amanda Littlewood-Evans, Bernadette Pöllinger, Jiri Kovarik, Janet Dawson, Gerhard Zenke, Christoph Burkhart, Matthias Müller, Hermann Gram.   

Abstract

OBJECTIVE: We have previously reported that the kinase activity of interleukin-1 receptor-associated kinase 4 (IRAK-4) is important for Toll-like receptor and interleukin-1 receptor signaling in vitro. Using mice devoid of IRAK-4 kinase activity (IRAK-4 KD mice), we undertook this study to determine the importance of IRAK-4 kinase function in complex disease models of joint inflammation.
METHODS: IRAK-4 KD mice were subjected to serum transfer-induced (K/BxN) arthritis, and migration of transferred spleen lymphocytes into joints and cartilage and bone degradation were assessed. T cell response in vivo was tested in antigen-induced arthritis (AIA) by measuring the T cell-dependent antigen-specific IgG production and frequency of antigen-specific T cells in the spleen and lymph nodes. T cell allogeneic response was tested in vitro by mixed lymphocyte reaction (MLR).
RESULTS: Lipopolysaccharide-induced local neutrophil influx into subcutaneous air pouches was impaired in IRAK-4 KD mice. These mice were also protected from inflammation in the K/BxN and AIA models, as shown by reduced swelling of joints. Histologic analysis of joints of K/BxN serum-injected mice revealed that bone erosion, osteoclast formation, and cartilage matrix proteoglycan loss were reduced in IRAK-4 KD mice. Assessment of T cell response by MLR, by frequency of antigen-specific clones, and by production of antigen-specific IgG did not reveal substantial differences between IRAK-4 KD and wild-type mice.
CONCLUSION: These results demonstrate that IRAK-4 is a key component for the development of proarthritis inflammation, but that it is not crucial for T cell activation. Therefore, the kinase function of IRAK-4 appears to be an attractive therapeutic target in chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19479877     DOI: 10.1002/art.24552

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  16 in total

1.  Membrane-bound toll-like receptors are overexpressed in peripheral blood and synovial fluid mononuclear cells of enthesitis-related arthritis category of juvenile idiopathic arthritis (JIA–ERA) patients and lead to secretion of inflammatory mediators.

Authors:  Arpita Myles; Mujeeb T Rahman; Amita Aggarwal
Journal:  J Clin Immunol       Date:  2012-06       Impact factor: 8.317

2.  Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner.

Authors:  Leah Cushing; Wayne Stochaj; Marshall Siegel; Robert Czerwinski; Ken Dower; Quentin Wright; Margaret Hirschfield; Jean-Laurent Casanova; Capucine Picard; Anne Puel; Lih-Ling Lin; Vikram R Rao
Journal:  J Biol Chem       Date:  2014-02-24       Impact factor: 5.157

3.  Loss of interleukin receptor-associated kinase 4 signaling suppresses amyloid pathology and alters microglial phenotype in a mouse model of Alzheimer's disease.

Authors:  Brent Cameron; Wayne Tse; Raza Lamb; Xiaoxia Li; Bruce T Lamb; Gary E Landreth
Journal:  J Neurosci       Date:  2012-10-24       Impact factor: 6.167

4.  Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4).

Authors:  Li Wang; Ryan Ferrao; Qiubai Li; John M Hatcher; Hwan Geun Choi; Sara J Buhrlage; Nathanael S Gray; Hao Wu
Journal:  J Biol Chem       Date:  2019-01-24       Impact factor: 5.157

Review 5.  Targeting Toll-like receptors: emerging therapeutics?

Authors:  Elizabeth J Hennessy; Andrew E Parker; Luke A J O'Neill
Journal:  Nat Rev Drug Discov       Date:  2010-04       Impact factor: 84.694

6.  IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.

Authors:  Leah Cushing; Aaron Winkler; Scott A Jelinsky; Katherine Lee; Wouter Korver; Rachael Hawtin; Vikram R Rao; Margaret Fleming; Lih-Ling Lin
Journal:  J Biol Chem       Date:  2017-09-18       Impact factor: 5.157

7.  A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase.

Authors:  Scott A Scarneo; Philip F Hughes; Kelly W Yang; David A Carlson; Deepak Gurbani; Kenneth D Westover; Timothy A J Haystead
Journal:  J Biol Chem       Date:  2019-12-30       Impact factor: 5.157

8.  Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.

Authors:  Michael Murphy; Goutham Pattabiraman; Tissa T Manavalan; Andrei E Medvedev
Journal:  Eur J Immunol       Date:  2017-03-31       Impact factor: 5.532

9.  Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors.

Authors:  W Michael Seganish; Thierry O Fischmann; Brad Sherborne; Julius Matasi; Brian Lavey; William T McElroy; Deen Tulshian; James Tata; Christopher Sondey; Charles G Garlisi; Kristine Devito; James Fossetta; Daniel Lundell; Xiaoda Niu
Journal:  ACS Med Chem Lett       Date:  2015-07-12       Impact factor: 4.345

10.  Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of Psoriasis.

Authors:  Satheesh Nair; Sreekantha Ratna Kumar; Venkatram Reddy Paidi; Ramesh Sistla; Durgarao Kantheti; Subba Rao Polimera; Soodamani Thangavel; Amrita Jha Mukherjee; Mitalee Das; Rajeev S Bhide; William J Pitts; Natesan Murugesan; Shailesh Dudhgoankar; Jignesh Nagar; Siva Subramani; Debarati Mazumder; Julie A Carman; Deborah A Holloway; Xin Li; Mark P Fereshteh; Stefan Ruepp; Kamalavenkatesh Palanisamy; T Thanga Mariappan; Srinivas Maddi; Ajay Saxena; Paul Elzinga; Anjaneya Chimalakonda; Qian Ruan; Kaushik Ghosh; Sucharita Bose; John Sack; Chunhong Yan; Susan E Kiefer; Dianlin Xie; John A Newitt; S Pon Saravanakumar; Richard A Rampulla; Joel C Barrish; Percy H Carter; John Hynes
Journal:  ACS Med Chem Lett       Date:  2020-06-10       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.